About 420 results

ALLMedicine™ Paronychia Center

Research & Reviews  138 results

Terminal Syme Amputation of the Great Toe in the Pediatric Population.
Journal of Pediatric Orthopedics; Gibson TW, Westberry DE et. al.

Aug 20th, 2021 - In the pediatric population, chronic ingrown toenails (onychocryptosis) can cause infection (paronychia), debilitating pain, and may be unresponsive to conservative treatments. Following multiple failed interventions, a terminal Syme amputation is...

Review of chemotherapy-associated paronychia.
International Journal of Dermatology; Gupta MK, Lipner SR

Jul 10th, 2021 - Chemotherapy-associated paronychia (CAP) is an inflammation of the nail folds in response to various chemotherapeutic medications. Altered proliferation of keratinocytes or nail matrix stem cells is thought to be a major causative factor. Prophyla...

Homogenization of the management of acute paronychia with abscess formation within the ...
Orthopaedics & Traumatology, Surgery & Research : OTSR; Matter-Parrat V, Lazarus P et. al.

Jun 9th, 2021 - There is no consensus in the literature, or even within the same team, on the most appropriate treatment option for acute paronychia with abscess formation. The performance of an evaluation of professional practices (EPP) using a clinical audit me...

Topical beta-blockers in dermatologic therapy.
Dermatologic Therapy; Filoni A, Ambrogio F et. al.

Jun 3rd, 2021 - An increasing use of beta-blockers in dermatology has been described over the last 10 years, despite the fact that their use in diseases other than infantile hemangiomas is off-label. This review discusses the emerging role of topical beta-blocker...

Surgical Intervention for Paronychia Induced by Targeted Anticancer Therapies.
Dermatologic Surgery : Official Publication for American ... Hanania HL, Pacha O et. al.

May 25th, 2021 - Paronychia is a common toxicity associated with targeted anticancer therapies. Antibiotics and steroids are the standard treatments for severe paronychia, yet they are often inadequate, prolonging the patient's suffering and resulting in changes t...

see more →

Guidelines  1 results

Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibito...
Drugs Califano R, Tariq N et. al.

Jul 19th, 2015 - Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib, erlotinib, and afatinib are standard-of-care for first-line treatment of EGFR-mutant advanced non-small cell lung cancer (NSCLC). These drugs have a prove...

see more →

Drugs  2 results see all →

News  26 results

FDA Approves Koselugo for Pediatric Neurofibromatosis Treatment

Apr 13th, 2020 - The Food and Drug Administration has approved selumetinib for the treatment of pediatric patients aged 2 years and older with type 1 neurofibromatosis (NF1) with symptomatic, inoperable plexiform neurofibromas. FDA approval was based on results fr...

Subungual Hemorrhage From an Epidermal Growth Factor Receptor Inhibitor
Josh A. Hammel, MD, Dean Elhag, MD et. al.

Jan 27th, 2020 - To the Editor: The epidermal growth factor receptor (EGFR) signaling pathway plays a role in the differentiation, proliferation, and survival of several cell types. 1 Erlotinib is an EGFR inhibitor that targets aberrant cells that overexpress this.

Green thumbnail
MDedge Family Medicine;

Aug 22nd, 2019 - The patient was given a diagnosis of green nail syndrome (GNS), an infection of the nail bed caused by Pseudomonas aeruginosa. These bacteria produce pyocyanin, a blue-green pigment that discolors the nail.

FDA approves oral dacomitinib for some metastatic NSCLC
Oncology Practice; Sharon Worcester

Sep 28th, 2018 - The Food and Drug Administration has approved dacomitinib tablets (VIZIMPRO) for the first-line treatment of metastatic non-small cell lung cancer in patients with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitut.

Triple Therapy Improves PFS in Certain Breast Ca Patients

Dec 28th, 2017 - Action Points Dual human epidermal growth factor receptor 2 (HER2) blockade with lapatinib (Tykerb) and trastuzumab (Herceptin) + an aromatase inhibitor (AI) improved progression-free survival (PFS) versus single HER2 blockade in HER2-positive/hor...

see more →

Patient Education  1 results see all →